Bonac Corporation (“Bonac”; HQ: Kurume City, Fukuoka; CEO: Hirotake Hayashi) announced the allocation of new shares (2.5 billion yen) to Toray Industries, Inc., Daiwa Japan-Taiwan Bio-Venture Investment Limited Partnership, SMBC Venture Capital No.2 Investment Business Limited Partnership, Shinsei Kigyo Investment Corporation, Mizuho Growth Support Investment Business Limited Partnership, and Chikugin Regional Revitalization Investment Business Limited Partnership to promote the development of therapeutic drugs for idiopathic pulmonary fibrosis and uveitis.

 

Bonac will continue to promote research and development so that our nucleic acid technology will become a bridge to drug discovery. 

 

Contact:

Corporate Affairs

press@bonac.co.jp